Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Lee Lichterman III who wrote (42769)	3/11/2000 6:53:00 PM
From: Casaubon	Read Replies (1) \| Respond to of 99985

Heck I will believe the new era internet hype before I will sign on to even half of these companies even being worth half these prices a few years from now. I believe biotech is just now beginning to hit its stride. There will be an acceleration of products entering the market place (in quicker turnaround times from lab to pharmacy. The average time for FDA approval is already on the decline, having shaved months off the approval process. The average time from concept to product is on the decline as well. And, I expect these trends to continue). Quicker turnaround time to drug products translate into higher profits for these companies as the patent life of the drugs get more time in the actual market rather than being delayed and eroded in clinical trials. BGEN looks like it will base here. It just tested gap support from mid january. siliconinvestor.com Look at the OBV on that chart. We are learning how the human machine works. This basic fact was in its infancy only 10 years ago. These products will not come cheap, not to develop, nor to use. There will be little pricing pressure and profits will remain strong for successful drug design companies. More people will need , and have, access to these products. Like any industry the strong will be much more valuable and the weak won't survive. BGEN, I suspect, will do fine. Don't buy the half which won't survive. Pipeline, patents, funding.